Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies (Armodafinil)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01256905|
Recruitment Status : Unknown
Verified April 2010 by New York University.
Recruitment status was: Recruiting
First Posted : December 9, 2010
Last Update Posted : December 9, 2010
|Condition or disease||Intervention/treatment||Phase|
|Parkinsons Disease Lewy Bodies Disease||Drug: Armodafinil||Not Applicable|
The main aims of this study are:
1. To investigate whether in PDD and DLB th specific disturbances in the basal ganglia thalamocortical network, measured through the Electroencephalography (EEG) frequency analysis, are ameliorated by armodafinil.
Our main hypothesis is that armodafinil can restore the attention and improve cognitive disturbances in PDD and DLB, through a specific effect on striatal-thalamo-cortical activity.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Attention Modulation for Treatment of Parkinson's Disease and Dementia With Lewy Bodies|
|Study Start Date :||December 2010|
|Estimated Primary Completion Date :||April 2011|
- EGI netstation software (Electrical Geodesics Inc.) and a custom made software that runs on the Matlab platform (The Mathworks) [ Time Frame: 2 hours ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01256905
|Contact: Sara Varanese, M.D.||212-263-4838 ext firstname.lastname@example.org|
|Contact: Jamika Y. Singleton-Garvin||212-263-7042||Jamika.Singleton-Garvin@nyumc.org|
|United States, New York|
|NYU Parkinsons and Movement Disorders Center||Recruiting|
|New York City, New York, United States, 10016|
|Contact: Sara Varanese, M.D. 212-263-4838 ext 3 email@example.com|
|Contact: Jamika Y Singleton-Garvin 212-263-7042 Jamika.Singleton-Garvin@nyumc.org|
|Principal Investigator: Sara Varanese, M.D.|
|Principal Investigator:||Sara Varanese, MD||NYU Parkinsons and Movement Disorders Center|